TY  - JOUR
AU  - Herling, Carmen D
AU  - Coombes, Kevin R
AU  - Benner, Axel
AU  - Bloehdorn, Johannes
AU  - Barron, Lynn L
AU  - Abrams, Zachary B
AU  - Majewski, Tadeusz
AU  - Bondaruk, Jolanta E
AU  - Bahlo, Jasmin
AU  - Fischer, Kirsten
AU  - Hallek, Michael
AU  - Stilgenbauer, Stephan
AU  - Czerniak, Bogdan A
AU  - Oakes, Christopher C
AU  - Ferrajoli, Alessandra
AU  - Keating, Michael J
AU  - Abruzzo, Lynne V
TI  - Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.
JO  - The lancet  / Oncology Oncology
VL  - 20
IS  - 11
SN  - 1470-2045
CY  - London
PB  - The Lancet Publ. Group
M1  - DKFZ-2019-02341
SP  - 1576-1586
PY  - 2019
N1  - 20(11):1576-1586
AB  - Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.
LB  - PUB:(DE-HGF)16
C6  - pmid:31582354
DO  - DOI:10.1016/S1470-2045(19)30503-0
UR  - https://inrepo02.dkfz.de/record/147215
ER  -